Literature DB >> 23699864

Comparison of final infarct volumes in patients who received endovascular therapy or intravenous thrombolysis for acute intracranial large-vessel occlusions.

Srikant Rangaraju1, Kumiko Owada, Ali Reza Noorian, Raul G Nogueira, Fadi Nahab, Brenda A Glenn, Samir R Belagaje, Aaron M Anderson, Michael R Frankel, Rishi Gupta.   

Abstract

IMPORTANCE: Studies comparing the efficacy of intra-arterial therapy (IAT) and medical therapy in reducing final infarct volume (FIV) in intracranial large-vessel occlusions (ILVOs) are lacking.
OBJECTIVES: To assess whether patients with ILVOs who received IAT have smaller FIVs than patients who received either intravenous tissue plasminogen activator therapy (IVT) or no reperfusion therapy (NRT) and to determine a National Institutes of Health Stroke Scale (NIHSS) threshold score that identifies patients most likely to benefit from IAT.
DESIGN: Retrospective cohort study of patients with ILVOs between 2009 and 2011.
SETTING: Two large-volume stroke centers. PARTICIPANTS: Adults with anterior circulation ILVOs who presented within 360 minutes from the time last seen as normal. Patients with isolated extracranial occlusions were not included. EXPOSURE: Intra-arterial therapy, IVT, or NRT. MAIN OUTCOMES AND MEASURES: Final infarct volumes, rates of acceptable outcome defined as a modified Rankin Scale score of 0 to 3 at hospital discharge, and NIHSS threshold scores.
RESULTS: A total of 203 consecutive patients with ILVOs were evaluated. Baseline characteristics were similar among the 3 groups. The median infarct volume was significantly smaller for the IAT group (42 cm3) than for the IVT group (109 cm3; P = .001) or the NRT group (110 cm3; P < .01). A higher magnitude of infarct volume reduction in more proximal occlusions was noted in the IAT group compared with the IVT and NRT groups combined: internal carotid artery terminus (75 vs 190 cm3; P < .001), M1 middle cerebral artery (39 vs 109 cm3; P = .004), and M2 middle cerebral artery (33 vs 59 cm3; P = .04) occlusions. Patients were stratified based on NIHSS score at presentation (8-13, 14-19, and ≥20). For patients with an NIHSS score of 14 or higher at presentation, IAT significantly reduced FIV (46 cm3 with IAT vs 149 cm3 with IVT or NRT; P < .001) compared with patients with an NIHSS score of 8 to 13 (22 cm3 with IAT vs 44 cm3 with IVT or NRT; P = .40). Patients with an NIHSS score of 14 or higher who received IAT appear to benefit most from IAT. CONCLUSIONS AND RELEVANCE: Our data suggest a greater reduction of FIV with IAT compared with either IVT or NRT. Moreover, patients with an NIHSS score of 14 or higher may be the best candidates for endovascular reperfusion therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23699864     DOI: 10.1001/jamaneurol.2013.413

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  8 in total

1.  Enrollment bias: frequency and impact on patient selection in endovascular stroke trials.

Authors:  Sunil A Sheth; Jeffrey L Saver; Sidney Starkman; Ileana D Grunberg; Judy Guzy; Latisha K Ali; Doojin Kim; Nestor R Gonzalez; Reza Jahan; Satoshi Tateshima; Gary Duckwiler; David S Liebeskind
Journal:  J Neurointerv Surg       Date:  2015-02-19       Impact factor: 5.836

2.  Predictors of functional dependence despite successful revascularization in large-vessel occlusion strokes.

Authors:  Zhong-Song Shi; David S Liebeskind; Bin Xiang; Sijian Grace Ge; Lei Feng; Gregory W Albers; Ronald Budzik; Thomas Devlin; Rishi Gupta; Olav Jansen; Tudor G Jovin; Monika Killer-Oberpfalzer; Helmi L Lutsep; Juan Macho; Raul G Nogueira; Marilyn Rymer; Wade S Smith; Nils Wahlgren; Gary R Duckwiler
Journal:  Stroke       Date:  2014-05-29       Impact factor: 7.914

3.  Mechanical embolectomy for acute ischemic stroke in the anterior cerebral circulation: the Gothenburg experience during 2000-2011.

Authors:  A Rentzos; C Lundqvist; J-E Karlsson; V Vilmarsson; K Schnabel; G Wikholm
Journal:  AJNR Am J Neuroradiol       Date:  2014-06-19       Impact factor: 3.825

4.  Predictors of Outcome following Stroke due to Isolated M2 Occlusions.

Authors:  Muhib Khan; Richard P Goddeau; Jayne Zhang; Majaz Moonis; Nils Henninger
Journal:  Cerebrovasc Dis Extra       Date:  2014-03-07

5.  Alberta Stroke Program Early CT Score Infarct Location Predicts Outcome Following M2 Occlusion.

Authors:  Muhib Khan; Grayson L Baird; Richard P Goddeau; Brian Silver; Nils Henninger
Journal:  Front Neurol       Date:  2017-03-14       Impact factor: 4.003

6.  The Natural History and Reperfusion Therapy Outcomes of Acute Ischemic Stroke due to Isolated M2 Occlusions.

Authors:  Hongmin Gong; Libo Zhao; Ge Tang; Yu Chen; Deyu Yang; Shudong Liu
Journal:  Biomed Res Int       Date:  2021-04-27       Impact factor: 3.411

7.  Automatic detection and quantification of acute cerebral infarct by fuzzy clustering and histographic characterization on diffusion weighted MR imaging and apparent diffusion coefficient map.

Authors:  Jang-Zern Tsai; Syu-Jyun Peng; Yu-Wei Chen; Kuo-Wei Wang; Hsiao-Kuang Wu; Yun-Yu Lin; Ying-Ying Lee; Chi-Jen Chen; Huey-Juan Lin; Eric Edward Smith; Poh-Shiow Yeh; Yue-Loong Hsin
Journal:  Biomed Res Int       Date:  2014-03-12       Impact factor: 3.411

8.  CT angiography and CT perfusion improve prediction of infarct volume in patients with anterior circulation stroke.

Authors:  Tom van Seeters; Geert Jan Biessels; L Jaap Kappelle; Irene C van der Schaaf; Jan Willem Dankbaar; Alexander D Horsch; Joris M Niesten; Merel J A Luitse; Charles B L M Majoie; Jan Albert Vos; Wouter J Schonewille; Marianne A A van Walderveen; Marieke J H Wermer; Lucien E M Duijm; Koos Keizer; Joseph C J Bot; Marieke C Visser; Aad van der Lugt; Diederik W J Dippel; F Oskar H W Kesselring; Jeannette Hofmeijer; Geert J Lycklama À Nijeholt; Jelis Boiten; Willem Jan van Rooij; Paul L M de Kort; Yvo B W E M Roos; Frederick J A Meijer; C Constantijn Pleiter; Willem P T M Mali; Yolanda van der Graaf; Birgitta K Velthuis
Journal:  Neuroradiology       Date:  2016-01-14       Impact factor: 2.804

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.